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NEGATIVE AFFECT AND VASOMOTOR SYMPTOMS  
IN THE DAILY HORMONE STUDY 
Carolyn Gibson, MS 
    University of Pittsburgh, 2011
 
Purpose: Vasomotor symptoms (VMS) are linked to poorer health and quality of life, and are 
common in the menopausal transition. Negative affect is consistently associated with self-
reported VMS, but interpretation of the temporal and directional nature of this relationship has 
been limited by potentially biased retrospective recall of VMS.  Using prospective data from 
end-of-day daily diaries, we examined the daily association and the day-to-day temporal 
relationship between negative affect and VMS.   
Methods: Data were from the third wave of the Daily Hormone Study (DHS) (n=625).  DHS is a 
substudy of the Study of Women’s Health Across the Nation (SWAN), a multi-site community-
based prospective cohort study of the menopausal transition.  Daily affect and VMS were 
reported in diaries over 12-50 days.  Multilevel mixed models, with daily observations nested 
within women, were used to determine the associations between daily diary-reported VMS and 
negative affect, adjusted by woman-level covariates (antidepressant use, age, education, 
menopausal status, self-reported health, and race/ethnicity) drawn from annual SWAN visits.   
Results:  Overall, VMS was reported on at least one day of observation by 327 women (52.3%).  
Women with higher average negative affect were more likely to ever report VMS (OR 1.79, 95% 
CI 1.30-2.45, p<.001).  Negative affect was also positively associated with VMS (OR 1.76, 95% 
CI 1.43-2.17, p<.001) within each 24 hour period.  Negative affect, adjusted by same day VMS, 
was not predictive of next day VMS (OR 1.107, 95% CI .85-1.35, p=.55), while VMS, adjusted 
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by same day negative affect, was predictive of negative affect the next day (OR 1.27, 95% CI 
1.03-1.58, p=.01).     
Conclusions: VMS and negative affect were positively associated with each other using 
prospective daily diaries.  Assessment of temporal relationships suggests that VMS precedes 
acute elevations in negative affect, but negative affect does not increase likelihood of VMS.      
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1.0  INTRODUCTION 
Hot flashes and night sweats, or vasomotor symptoms (VMS), are common during the 
menopausal transition.   These symptoms are reported by an estimated 70-80% of women, and 
increase in prevalence with advancing menopausal stage (Gold, 2006).  The frequency, duration, 
severity, and bothersomeness of VMS are highly variable, and explanatory mechanisms for these 
differences in experience are only partially understood.  Smoking, obesity, SES, and race are 
associated with symptom occurrence and characteristics of VMS presentation, while measures of 
negative affect appear to be among the strongest and most consistent correlates of VMS (Woods, 
2005).     
VMS have a negative impact on quality of life, and emerging associations with health 
functioning and cardiovascular risk factors (Thurston, 2008b) suggest that the underlying factors 
or ramifications of these symptoms have an impact on physical health that has not been 
previously recognized.  Achieving a better understanding of the relationship between VMS and 
their common correlates may elucidate information about the mechanisms behind these events.  
Understanding mechanisms may also have an impact on intervention, improving quality of life 
and alleviating the health concerns related to VMS.  While the current literature has established 
that negative mood and VMS are strongly associated, limitations in study design do not allow for 
an understanding of the temporal associations of these factors, or whether the association is still 
present when retrospective recall that may be biased by affect is limited. 
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This study aimed to use novel data collection to increase our understanding of the 
association between negative mood and VMS, with a focus on determining the nature of the 
temporal relationship between these factors.  The following pages review the common 
presentation, course, and prevalence of VMS, the possible health implications of VMS, and 
current etiological theories.  The common correlates of VMS seen in the literature are detailed 
next, with an emphasis on the relationship between VMS and negative mood.  The limitations of 
the current literature preventing a better understanding of these associations and directionality 
are discussed.  The study design and analytic plan are then presented, followed by results and a 
discussion of the study’s findings.      
2.0  LITERATURE REVIEW 
 
2.1 VASOMOTOR SYMPTOMS 
Vasomotor symptoms (VMS), commonly referred to as hot flashes and night sweats, are 
experienced as temporary sensations of intense heat accompanied by sweating and flushing 
(Thurston, 2009a), peaking within a minute and subsiding altogether within about five minutes 
(Freedman, 2001).  VMS are preceded by an increase in core body temperature, and 
accompanied by peripheral vasodilation and increased skin temperature, blood flow, sweating, 
and skin conductance (Freedman, 2005).  VMS are a common experience of the menopausal 
transition, reported by an estimated 70-80% of women.  Prevalence increases with advanced 
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menopausal stages, with symptoms most often occurring in the late perimenopause and early 
post-menopause (Gold, 2006).  An estimated 30% of women with daily VMS report a frequency 
of 10 or more occurrences each day (Freedman, 2001).  VMS are generally experienced over a 
period of 1-5 years before subsiding, with a median duration of 4 years (Freedman, 2001).  
However, an estimated 20-30% of women continue to experience VMS for 10-15 years or longer 
(Barnabei, 2005).  In addition to individual variations in duration, the severity, frequency 
(Woods, 2005), and perceived bother (Thurston, 2008a) of VMS are highly variable.   
2.2 ETIOLOGY OF VASOMOTOR SYMPTOMS 
The etiology underlying VMS and driving individual differences in symptom presentation is 
unclear.  VMS are common in women during the menopausal transition and following natural 
and surgical menopause, suggesting an etiological role of estrogen withdrawal.  Adding support 
to this theory is the general efficacy of exogenous estrogen administration in decreasing or 
eliminating VMS occurrence.  However, VMS are not experienced by all women experiencing 
either gradual or sudden estrogen withdrawal (Freedman, 2005).   
The thermoregulatory theory may partially explain VMS etiology. The sweating and 
peripheral vasodilation characteristic of VMS are heat dissipation events that naturally occur 
when core body temperature exceeds the upper threshold of the body’s thermoneutral zone, the 
temperature range sufficient for function.   In symptomatic women, the entire thermoneutral zone 
may be narrowed and the upper threshold lowered, allowing VMS to be triggered with small 
fluctuations in core body temperature (Freedman, 2005). Estradiol affects the hypothalamic 
thermoregulatory center as well as serotenergic, adrenergic, and norepinephrine 
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neurotransmitters (Joffe, 2007).  Fluctuating estradiol levels typical in the perimenopause may 
therefore negatively impact thermoregulation.  Neural norepinephrine, which seems to be higher 
in symptomatic women and increases with VMS, may be the mediator for alteration of the 
thermonetural zone (Keefer, 2005).   
2.3 HEALTH IMPLICATIONS OF VASOMOTOR SYMPTOMS 
VMS are commonly associated with decreases in quality of life and sleep disturbance (Avis, 
2009). VMS may also have a significant clinical impact beyond their effects on quality of life.   
An estimated one-third of women with VMS seek medical attention, with increased utilization 
among women with frequent or bothersome VMS (Williams, 2007). Though VMS are a primary 
driver of treatment-seeking for menopausal problems (Guthrie, 2003), treatment-seeking is not 
limited to attempts to alleviate these symptoms.  
VMS have increasingly been associated with overall poor health, with an emerging 
literature linking VMS to cardiovascular risk factors and indices of subclinical cardiovascular 
disease (Thurston, 2008b).  VMS occurrence was associated with significant health decline over 
time in a prospective analysis of Whitehall II, with concordance between the severity of health 
decline over the menopausal transition and the severity of self-reported symptoms (Kumari, 
2005).  In the Melbourne Women’s Midlife Health Project, a longitudinal sample of midlife 
women in Australia, bothersome VMS were associated with declining ratings of self-rated health 
(Dennerstein, 2003).  In recent studies, associations between VMS, cardiovascular disease risk 
factors, and subclinical coronary heart disease have also been found.  VMS may be associated 
with higher BMI, waist-hip ratio, total cholesterol level, LDL level, triglycerides level, glucose 
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level, and systolic and diastolic blood pressure (Gast, 2010), reduced high-frequency heart rate 
variability (Thurston, 2010a; Hoikkala, 2010), impaired endothelial function (Thurston, 2008b; 
Bechloulis, 2010) increased aortic calcified plaque (Thurston, 2008b; Thurston, 2010b), and 
increased intima media thickness (Thurston, in press).  At this time, it is not known whether 
VMS increases health risks, occur more frequently due to poor health, or whether underlying 
factors increase the risk for both VMS and poor health among women in midlife.     
2.4 COMMON CORRELATES OF VASOMOTOR SYMPTOMS 
Research on the menopausal transition has elucidated several factors that tend to be associated 
with VMS.  Both active and passive smoke exposure are associated with VMS, though the 
mechanisms linking exposure with symptoms is unclear (Gold, 2004). Regular physical activity 
may be associated with a lower prevalence and lower severity of VMS (Ivarsson, 1998; Gold, 
2004), though evidence of this association is highly mixed (Greendale, 2005).  Self-reported 
VMS have been associated with difficulty falling asleep and sleep disruption in SWAN and other 
samples, and women often report sleep disruption due to night sweats (Kravitz, 2008).  Higher 
body fat percentage (Thurston, 2008b) and body mass index (BMI) (Freeman, 2001), as well as 
increasing body fat over the menopausal transition are associated with increased self-reported 
VMS (Thurston, 2009b).  VMS experience appears to vary by race/ethnicity, with the highest 
prevalence seen among African American women and the lowest seen among Asian women. 
Whether these differences are due to physiological or cultural reporting issues is unclear (Gold, 
2006).  VMS is also more likely to be reported among women with low socioeconomic status, 
generally measured by educational attainment (Gold, 2006; Schwingl, 1994). As described 
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below, the prevalence, frequency, severity (Woods, 2005), and bothersomeness of VMS are 
associated with anxiety, depressive symptoms, and other measures of negative affect (Thurston, 
2008a). 
2.5 NEGATIVE AFFECT AND VASOMOTOR SYMPTOMS 
Evidence relevant to the associations between self-reported VMS and measures of negative 
affect come from three types of literatures: (1) cross-sectional studies where concurrent measures 
of negative mood and VMS are examined; (2) longitudinal and experimental studies where 
concurrent measures of negative mood and VMS are examined over time; and (3) studies that 
use longitudinal data, experimental findings, and/or statistical methods such as path analysis to 
examine the associations of negative mood at one point in time in relation to VMS at another 
point in time, and vice versa.  We now discuss each of these types of evidence, as noted in 
Tables 1 – 3.   
2.5.1 Findings from cross-sectional studies 
There are 17 cross-sectional studies relevant to this topic in the literature.  Thirteen found an 
association between concurrently measured negative affect and VMS (table 1).  This relationship 
was obtained in studies representing varied populations, varied characteristics of VMS, and 
varied measures of mood.  Mood and VMS were generally self-reported, using either validated 
questionnaires or ad hoc symptom reporting to assess mood and VMS experience in the previous 
2-4 weeks.  Associations were found between the presence, frequency, severity, and bother of 
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self-reported VMS and depressive symptoms (Blumel, 2004; Brown, 2008; Joffe, 2002; 
Thurston, 2009b; Thurston, 2008a; Cheng, 2008; Hunter, 2009; Li, 2008; Seritan, 2010), anxiety 
(Blumel, 2004; Cheng, 2008; Hunter, 2009; Li, 2008; Seritan, 2010; Thurston, 2009b; Thurston, 
2008a), psychologic distress (Bromberger, 2001; Bromberger, 2003; Ishizuka, 2008), and 
negative affect (Collins, 1994; Thurston, 2008a). These associations have been seen in samples 
in the US (Bromberger, 2003; Bromberger, 2001; Brown, 2009; Joffe, 2002; Seritan, 2010; 
Thurston, 2008a; Thurston, 2009b), Chile (Blumel, 2004), Taiwan (Cheng, 2008), Japan 
(Ishizuka, 2008), China (Li, 2008), Sweden (Collins, 1994), India, and the UK (Hunter, 2008).  
Findings also indicate that negative affect is a significant correlate of VMS bother, even 
adjusting for frequency (Thurston, 2008a), implicating a role of mood in the subjective 
experience of symptoms.   
Although the majority of studies reported this association, there were some notable 
exceptions. Though significantly associated in unadjusted models, VMS and depressive 
symptoms were no longer associated in adjusted models in two community samples.  In one 
study, this may have been due to the simultaneous entry of hot flashes and night sweats entered 
separately, rather than considered together as highly correlated measures of VMS (Bosworth, 
2001).  In the second study, prevalence of VMS and depressed mood were low, which may have 
limited their ability to find associations.  Additionally, the association was not longer seen after 
adjusting for insomnia, though VMS continued to predict fatigue, which was associated with 
depressed mood (Elavsky, 2009).  The relationship between VMS and depressed mood may be 
mediated by sleep disturbance attributable to night sweats.  No association between VMS and 
depression was seen in two investigations that used current SCID-diagnosed depression (Ozturk, 
2006; Schmidt, 2004a) rather than a more commonly reported measure of depressive symptoms.  
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This suggests that VMS may be more strongly related to mood symptoms rather than clinically 
significant mood disorders, or may be due to decreased power to identify an association given 
the lower number of individuals meeting diagnostic criteria. Additionally, subanalyses of some 
studies suggest that mood and VMS associations may be strongest in perimenopausal women.  
VMS were associated with anxiety in perimenopausal and post-menopausal Taiwanese women, 
though not premenopausal women (Cheng, 2008).  Seritan et al. found a larger effect of VMS in 
perimenopausal women compared to post-menopausal women (Seritan, 2010), and in Joffe et 
al.’s (2002) sample of women seeking primary care, depressive symptoms were only linked to 
VMS in perimenopausal women, with no relationship seen among premenopausal and 
postmenopausal women.   
Table 1.  Cross-sectional studies 
Author 
(year) 
Sample Subject VMS measure Affect measure Supports 
VMS/affect 
association? 
Blumel 
(2004) 
N=300 
Age=40-59 
Sample=Chilean community 
sample 
Role of biological and 
psychosocial factors in 
prevalence of menopausal 
symptoms 
Self-reported VMS current 
bother (Greene Climacteric 
Scale) 
Anxiety (Greene Climacteric Scale), 
depression (Greene Climacteric Scale) 
Yes 
Bromberger 
(2003) 
N=3302 
Age=42-52 
Sample=SWAN  
Persistent mood symptoms in 
pre- and early perimenopause 
Self-reported VMS frequency 
in previous two weeks 
Psychologic distress (frequency of 
feling blue or depressed, irritability of 
grouchiness, feeling tense or nervous, 
frequent mood changes) 
Yes 
Bromberger 
(2001) 
N=16,065 
Age:  42-54 
Sample=SWAN screener 
Psychologic distress and 
menopause 
Self-reported VMS 
occurrence in previous two 
weeks 
Psychologic distress (frequency of 
feeling tense/nervous, feeling blue or 
depressed, and feeling irritable or 
grouchy in previous 2 weeks ) 
Yes 
Brown 
(2009) 
N=639 
Age=45-54 
Sample=Population-based 
community sample 
Menopausal symptoms, sleep 
disturbance, and depressive 
symptoms 
Self-report: occurrence and 
frequency of daytime and 
nocturnal hot flashes in 
previous 30 days 
Depressive symptoms (CES-D) Yes 
 
 
Cheng 
(2008) 
N=1113 
Age=43-57 
Sample=Taiwanese 
community sample 
Relationship between sleep 
disturbance, mood, 
menopausal status, and VMS. 
Self-reported VMS 
occurrence in previous 2 
weeks 
Anxiety (Chinese version of the 
Hospital Anxiety Depression Scale 
(HADS)), depression (Chinese version 
of the Hospital Anxiety Depression 
Scale (HADS)) 
Yes  
Collins 
(1994) 
 
 
N=2011 
Age=48 
Swedish community sample 
Reproductive health, use of 
estrogen and experience of 
menopausal symptoms in 
perimenopausal women 
Self-reported frequency of 
VMS (adapted from The 
Menopause Symptom 
Inventory (MENSI)) 
Negative mood (self-reported tension, 
feeling depressed, spells of crying; 
adapted from The Menopause 
Symptom Inventory (MENSI)) 
Yes 
Hunter 
(2008) 
N=153 
Age=45-55 
Caucasian and Southeast 
Asian women in UK, 
Southeast Asian women in 
India 
Cultural differences in the 
menopausal experience 
Self-reported VMS 
occurrence in previous two 
weeks (Women’s Health 
Questionnaire, vasomotor 
subscale) 
Anxiety, depressed mood (Women’s 
Health Questionnaire, anxiety 
subscale, depression subscale) 
Yes  
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Table 1 (Continued) 
 
Ishizuka 
(2008) 
N=1169 
Age=50 
Urban Japanese 
community sample 
Prevalence and 
characteristics of 
menopausal symptoms in 
Japanese women 
Self-reported VMS 
occurrence 
Psychological stress (endorsing unease or anxiety) Yes 
Joffe 
(2002) 
N=476 
Age=40-60 
Primary care patients 
VMS in depression in 
perimenopausal v. pre- 
and postmenopausal 
women 
Self-report: occurrence of 
VMS within previous 30 
days  
Depressive symptoms (CES-D) 
 
Yes  
Li (2008) N=1280 
Age=45-59 
Urban Chinese  
community sample  
Prevalence of depression 
and anxiety, and their 
influence, in menopause 
Self-reported VMS 
occurrence in previous 
year 
Anxiety (Zung Self-rating Anxiety Scale), depression (Zung Self-
rating Depression scale) 
Yes 
Seritan 
(2010) 
N=487 
Age=40-64 
Retrospective chart 
review, California 
menopausal sx patients 
Anxiety, depressive 
symptoms, and VMS in 
perimenopause 
Self-reported occurence 
and bothersomeness of 
VMS in previous several 
weeks 
Depressive symptoms (clinical intervew and response to “I have 
more depressed moods.” 
Anxiety symptoms (clinical interview and response to, “I feel more 
anxious than usual.” 
(anxiety and depressive symptoms combined) 
Yes  
Thurston 
(2008) 
N=1042 
Age=49-61 
SWAN visit 7 
Predictors of VMS bother Self-report of VMS 
occurrence, frequency, 
and bother in previous 2 
weeks 
Negative affect (index comprised of negative mood—PANAS, 
depressive symptoms—CES-D, trait anxiety—Spielberger State 
Trait Anxiety Inventory, anxious symptoms—sum score of 
responses to 4 questions about irritability, nervousness, heart 
punding, and feeling fearful in past 2 weeks, and perceived stress—
Perceived Stress Scale) 
Yes  
Thurston 
(2009b) 
N=30 
Age=40-60 
Sample=late peri- and 
postmenopausal 
women with VMS 
Laboratory hot flash 
classification methods 
Self-reported VMS as 
occurring in laboratory 
(event marker) 
Depressive symptoms (CES-D), anxiety (Spielberger State Trait 
Anxiety Inventory) 
Yes  
Bosworth 
(2001) 
N=581 
Age=45-54 
Community sample 
Predictors of depression 
in perimenopause 
Self-reported VMS 
occurrence 
Depressive symptoms (CES-D) No  
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Elavsky 
(2009) 
N=212 
Age=45-65 
TREMIN Research Program on 
Women’s Health 
Depressed mood and fatigue as 
mediators between physical 
activity, BMI, VMS, and 
perceived stress 
Self-reported VMS bother in previous 
year 
Depressed mood (degree to 
which self-reported “feeling 
depressed/having the blues” in 
previous year) 
No  
Ozturk 
(2006) 
N=151 
Age=40-54 
Depressed and non-depressed pre-and 
perimenopausal Turkish sample 
recruited from University 
perimenopause and outpatient 
psychiatry clinics 
Comparison of depression and 
rsik factors in perimenopausal 
and premenopausal women 
Self-reported current VMS bother 
(Greene Climacteric Scale) 
Depression (SCID, Hamilton 
Depression Scale, Montgomery 
Asberg Depression Scale) 
No 
Schmidt 
(2004a) 
N=100 
Age=44-55 
depressed and non-depressed 
perimenopausal women 
Stressful life events, loss, and 
depression in the 
perimenopause 
Presence v. absence of VMS based on 
mean severity/frequency of VMS self-
reported on Daily Rating Form in 
previous 8 weeks 
Depression (SCID) No 
 
 
 
2.5.2 Findings from longitudinal studies 
As noted in Table 2, there are 12 reports on concurrently measured associations across time in 
longitudinal studies.  The presence, frequency, and severity of VMS were associated with 
measures of negative affect over a range of 3 to 15 years in 9 studies.  This relationship was 
found in 4 studies that used repeated measures regression models with depressive symptoms as 
the outcome, with VMS as a covariate and both factors assessed at all annual observations over 
3-8 years (Avis, 2001; Avis, 1994; Bromberger, 2010; Dennerstein, 1999) and 2 studies that used 
repeated measures regression models with VMS as the outcome, with anxiety (Freeman, 2005; 
Gold, 2006) and depressive symptoms (Gold, 2006) as independent variables, and both factors 
assessed at all annual observations over 6-8 years.  In two samples of women followed over the 
menopausal transition, ever reporting VMS during the observed period was associated with an 
increased risk of depression during that same period (Schmidt, 2004b; Cohen, 2006).  Schmidt et 
al. followed premenopausal women until they reported amenorrhea for at least 6 months, a mean 
of 5 years; depression was assessed with SCID every 6 months, and daily VMS reports were 
collapsed into ever/never VMS over the observed period.  Depressive symptoms were assessed 
every 6 months for 3 years, and VMS in the previous 6 months were self-reported at the final 
follow-up in Cohen et al.(2006).  Finally, in an assessment of changing risk for depressive 
symptoms within women over eight years of the menopausal transition, it was found that women 
were twice as likely to report VMS at annual visits concurrent with high levels of depressive 
symptoms relative to those visits when their depressive symptoms were low (Freeman, 2006).  
These positive findings were seen in varied samples of women in the US (Avis, 2001; Avis, 
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1994; Freeman, 2006; Freeman, 2005; Gold, 2006; Schmidt, 2004b) and Australia (Dennerstein, 
1999).  
This relationship was not seen in all studies.  Two analyses of the Seattle Midlife 
Women’s Health Study (SMWHS) did not find a relationship between self-reported VMS 
severity and self-reported severity of depressed or sad mood.  In a small subsample, both 
variables were reported concurrently in daily diaries over a period of three days every 1-3 
months for a mean of 6 years, with within-woman correlations of individual annual averages of 
mood and VMS assessed (Woods, 2007).  In a separate SMWHS analysis, depressed mood as 
measured annually for up to 15 years by the CES-D was related to retrospectively self-reported 
past-year VMS in unadjusted though not adjusted models (Woods, 2008).  The authors speculate 
that sleep disturbance, which was related to VMS and to depressed mood in the first paper and 
not assessed in the second, may mediate the relationship between VMS and mood.  Among the 
three longitudinal studies that examined diagnosed depression and VMS, one small sample 
(Schmidt, 2004b) found an association between ever reporting VMS over a mean of 5 years 
observation and perimenopausal depression as assessed by SCID every 6 months, while two 
other analyses of large, population-based samples (Bromberger, 2009; Freeman, 2006) with 
annual measures of VMS and depression did not.  In one within-woman analysis of the Penn 
Ovarian Aging Study (POAS), depression as diagnosed by PRIME-MD was not associated with 
VMS, while depressive symptoms as measured by CES-D were (Freeman, 2006).  All VMS and 
mood assessments were completed every 8-12 months over 8 years of observation.  The authors 
suggested that power may have been limited to find a relationship in the small number of women 
with diagnosable depression.  This outcome is consistent with the previously reviewed findings 
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of SCID-diagnosed depression in the cross-sectional literature; the relationship between VMS 
and depressive symptoms may be stronger than that between VMS and clinical diagnoses. 
Overall, findings from cross-sectional and longitudinal studies in which VMS and mood 
are assessed concurrently largely support an association between measures of negative mood and 
self-reported VMS.  This relationship is present in a variety of samples, with varying measures 
of mood and self-reported VMS, and persists over time.  The relationship appears strongest in 
the perimenopause, and with measures of symptoms rather than diagnosable mood disorders.  
However, the nature of this relationship is not known.  The temporal relationship between these 
factors cannot be determined from the literature reviewed, and few investigators purposefully 
attempt to address it. 
Table 2.  Longitudinal studies 
 
Author 
(year) 
Sample Subject VMS measure Affect measure Outcome 
of interest 
Supports 
VMS/affect 
association? 
Avis (2001) N=309 
Age=43-53 
Sample=Massachussetts Women’s 
Health Study 
Timeframe=3 years 
Association between 
depression and estradiol 
in menopause 
Self-reported VMS 
occurrence 
Depressive 
symptoms (CES-D) 
Depressed 
mood 
Yes 
Avis (1994) N=2565 
Age=43-53 
Sample=Massachussetts Women’s 
Health Study 
Timeframe=5 years 
Menopausal status and 
depression 
Self-reported VMS 
occurrence 
Depression Depressed 
mood 
Yes 
Bromberger 
(2010) 
N=3302 
Age=42-52 
Sample=Study of Women’s Health 
Across the Nation 
Timeframe=8 years 
Hormone levels and 
depressive symptoms in 
menopause 
Self-reported VMS 
occurrence in 
previous two weeks 
Depressive 
symptoms (CES-D) 
Depressed 
mood 
Yes 
Cohen 
(2006) 
N=460 
Age=36-45 
Sample=premenopausal women with 
no history of depression from 
Harvard Study of Mood and Cycles 
Timeframe=3 years 
Menopausal transition 
and risk for new onset 
of depression 
Self-reported VMS 
presence in 
previous 6 months 
Depressive 
symptoms (CES-D) 
Depressed 
mood 
Yes  
Dennerstein 
(1999) 
N=354 
Age=45-55 
Sample=MWMHP (Australia) 
Timeframe=6 years 
Predictors of negative 
mood in menopause 
Self-reported 
bothersome VMS 
in previous 2 weeks 
Negative moods 
(Affectometer-2 
subscale) 
Negative 
mood 
Yes  
Freeman 
(2006) 
N=231 
Age=35-47 
Sample=Penn Ovarian Aging Study 
Timeframe=8 years 
Menopausal status and 
hormonal changes as 
predictors of depression 
in menopause 
VMS occurrence, 
frequency, and 
severity in previous 
month 
Depressed mood 
(CES-D) 
Depressed 
mood 
Yes  
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Table 2 (Continued) 
 
Freeman (2005) N=436 
Age=35-47 
Sample=Penn Ovarian Aging 
Study 
Timeframe=6 years 
Anxiety and hormonal 
changes as predictors of 
VMS 
VMS occurrence, 
frequency, and severity 
in previous month 
Anxiety (Zung Anxiety 
Index) 
VMS Yes 
Gold (2006) N=3198 
Age=42-54 at baseline 
Sample=SWAN 
Timeframe=6 years 
Race/ethnicity and VMS Self-reported VMS 
occurrence in previous 
2 weeks 
Anxiety (sum score of 
responses to four 
questions), depressive 
symptoms (CES-D) 
VMS Yes 
Schmidt 
(2004b) 
N=29 
Age=45-55 
Sample=asymptomatic 
premenopausal volunteers 
Timeframe=mean 5 years 
(until postmenopausal) 
Menopausal status and 
depression 
Self-reported VMS 
occurrence (confirmed 
by daily ratings) 
Depression (SCID) Depression Yes 
Bromberger 
(2009) 
N=266 
Age=42-52 
Sample=Study of Women’s 
Health Across the Nation 
Timeframe=7 years 
Predictors of incident 
depression in midlife 
Self-reported VMS 
occurrence in previous 
two weeks 
Depression (SCID) Depression No 
Woods (2008) N=302 
Age=35-55 
Sample=Seattle Midlife 
Women’s Health Study 
Timeframe-15 years 
 
Depressed mood in the 
menopausal transition 
Self-reported 
occurrence and severity 
of VMS in previous 
year 
Depressed mood (CES-D) Depressed 
mood 
No  
Freeman (2006) 
(repeat entry; 
separate 
analysis) 
N=231 
Age=35-47 
Sample=Penn Ovarian Aging 
Study 
Timeframe=8 years 
Menopausal status and 
hormonal changes as 
predictors of depression in 
menopause 
VMS occurrence, 
frequency, and severity 
in previous month 
Depression (PRIME-MD) Depression No  
Woods (2007) N=41 
Age=35-47 
Sample=SMWHS 
Timeframe=8 years 
Menopausal symptoms and 
hormonal changes in the 
menopausal transition 
VMS occurrence and 
severity self-reported in 
daily diaries for 3 days 
Depressed mood (daily 
diary) 
Depressed 
mood, VMS 
No 
 
2.5.3 Studies addressing temporal association 
2.5.3.1  Treatment studies  Though not specifically designed to test the temporal relationship 
between mood and VMS, experimental studies examining interventions for VMS that are 
traditionally used to alleviate negative mood symptoms and/or reduce stress, such as 
pharmacological treatment with SSRIs or SNRIs, could be utilized to assess the temporal 
relationship between mood and VMS.  VMS reduction secondary to improvements in mood 
would suggest that mood precipitates and influences VMS presentation; simultaneous 
improvement in mood and VMS may suggest that a third factor affected by the treatment, such 
as serotenergic function, underlies both factors. However, evidence from these trials is limited.  
Studies are generally small, of short duration, and largely comprised of women with a history of 
breast cancer, which may have a different influence on VMS etiology and treatment (Suvanto-
Luukkonen, 2005).  Further, mood changes are not often measured, and the temporal association 
between changes in mood and VMS is not usually tested.   
Six studies assessed mood as well as VMS changes, but the sample sizes in four are too 
small for interpretation (Joffe, 2007; Ladd, 2005; Schmidt, 2000; Soares, 2006).   In the two 
trials with sufficient sample size (Gordon, 2006; Suvanto-Luukkonen, 2005), there was 
improvement in both mood and VMS, but changes in these factors were not related (Suvanto-
Lukkonen, 2005), and VMS reductions were not attributable to treatment effects on mood 
(Gordon, 2006).  However, the trial duration in one trial of sufficient sample size was only 4 
weeks (Gordon, 2006), and it is possible that this timeframe was not sufficient to see possible 
VMS reductions attributable to continued mood improvement.  Further, there was a substantial 
VMS reduction in response to placebo in both trials, an effect which has been reported to exceed 
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30% in several treatment studies (van Die, 2009).  The placebo effect may be specific to the 
subjective experience of symptoms; placebo response was seen with self-reported VMS, but not 
with physiologically measured VMS, in one study of breast cancer survivors (Carpenter, 2007).  
Overall, pharmacological treatment appears to have an effect on VMS that may be mediated by 
central nervous system changes or mood effects on appraisal, but current investigations do not 
adequately examine these relationships to contribute to conclusions. 
2.5.3.2  Epidemiological Studies  Data from epidemiological studies can offer information 
about the temporal relationship between affect and VMS assessed in annual assessments.  To that 
end, six analyses of longitudinal samples are discussed below.  Two analyses of the Penn 
Ovarian Aging Study (POAS) that set out to examine the temporal association between these 
factors suggest that mood precedes VMS.  In a lagged analysis predicting self-reported VMS in 
the past month at each annual assessment over 6 years, previous-year anxiety scores (Zung 
Anxiety Scale) and anxiety score change over the past year predicted VMS as well as initial 
VMS onset  (Freeman, 2005).  However, the alternate pathway, VMS preceding anxiety, was not 
tested.  In another within-woman assessment of women without VMS or depressive symptoms at 
baseline, depressed affect occurred prior to VMS in 24% of the women who subsequently 
experienced both over the 10-year observed period; this relative risk is twice what would be 
expected if the two symptoms were due to entirely independent processes (Freeman, 2009).  In 
the POAS, both anxiety and depressive symptoms seem to precede VMS onset when both are 
measured annually and assessed over the menopausal transition.  Other longitudinal studies 
confirmed predictive pathways over the menopausal transition with either VMS or depressive 
symptoms as the outcome.  Consistent with Freeman et al. (2004, 2009), two studies predicted 
VMS at follow-up from baseline measures of depressive symptoms four years (Freeman, 2001) 
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and nine years (Guthrie, 2005) previously, and one survival analysis with depressive symptoms 
as a biennially measured time-varying covariate predicted the onset of VMS and other 
menopausal symptoms over a 10 year period (Sabia, 2008). In contrast, depressive symptoms in 
the final study visit were predicted from annual observations of VMS and other factors over the 
previous 10 years in another epidemiological sample (Dennerstein, 2004).  While these 
longitudinal samples suggest that measures of affect at one point in time can predict VMS at 
another, and that VMS over time can predict later depressive symptoms, only the analyses of the 
POAS were purposefully designed to test which factor appears to precede the other over time.     
2.5.3.3   Ambulatory and Daily Diary Studies  As opposed to the summary measures of mood 
and VMS collected in treatment and epidemiological studies, ambulatory and daily diary data 
can be utilized to investigate the relatively acute effects of mood on VMS, and vice versa.  These 
prospective data collection methods also limit the potential bias of long-term retrospective recall. 
Thurston et al. (2005) investigated the effect of acute emotional arousal on VMS over the course 
of two days using ambulatory physiologic and self-report VMS measurement.  Mood ratings 
were collected on a fixed schedule three times an hour, self-reported VMS were self-reported as 
they occurred, and skin conductance was continually monitored for physiologically measured 
VMS. Self-reported VMS not accompanied by physiological evidence were more likely in 
women whose responses to psychometric questionnaires at the initiation of data collection 
indicated overall increased depression, state anxiety, trait anxiety, and somatization, and self-
reported VMS tended to occur after periods of increased frustration.  This relationship was not 
seen with physiologically measured VMS, which were more likely after positive rather than 
negative emotional states.  Self-reported VMS was both precipitated by negative emotion and 
more common in women with increased negative mood (Thurston, 2005).  The difference 
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between physiologically measured and self-reported VMS suggests the importance of mood 
specifically in the subjective experience of symptoms.   
Other studies have used daily diaries and path analysis to examine VMS as a precipitant 
of negative mood. VMS reported in daily diaries over five days were used in a structural 
equation model analysis designed to test a proposed pathway from VMS to an annual measure of 
depressed mood in women in midlife.  This analysis of the Seattle Midlife Women’s Health 
Study (SMWHS) did not find a direct effect of VMS on depressed mood (Woods, 1997).  The 
lack of association in this study may stem from several factors.  First, VMS severity rather than 
occurrence or frequency was used to assess VMS.  However, severity was low in this sample, 
with a mean value suggesting that most women experienced no symptoms, or few symptoms 
with limited severity.  The limited symptom experience may explain the absence of an 
association, and may be due to the fact that data were drawn from the first year of collection, 
when only a small percentage of women appeared to have begun the transition to perimenopause.  
As previously discussed, the association between mood and VMS may not be consistently seen 
in women outside of perimenopause.   
Burleson et al. (2010) collected daily diary ratings of VMS and mood items from 55 
healthy women in midlife over up to 5 years.  They created a structural equation model using 252 
contiguous, highly symptomatic days for each woman to test the direct relationship between 
VMS and next-day mood, and a mediated relationship between VMS and mood by way of sleep 
problems.  VMS predicted lower next-day positive mood and higher next-day negative mood, 
but only in women who did not have high depression scores at study entry (Burleson, 2010).  
While the findings supported the theory that VMS precedes mood over short periods of time, the 
effect on acute mood states was only seen in women without high stable measures of negative 
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affect.  Further, although a number of models indicating potential causal pathways can be 
statistically supported when two factors are significantly correlated (SPSS Wikia, 2010), 
alternate path models were not reported; interpretation may have been biased by a priori 
assumptions of directionality.  Finally, only half of this small sample had reached 
perimenopausal status at the initiation of data collection, and as previously reported, the 
association between affect and VMS may not be present or as strong in non-perimenopausal 
women.  This analysis did not adjust for menopausal status or any other woman-level covariates.     
Overall, studies that test or offer information about the temporal associations between mood and 
VMS are few, and yield mixed evidence.   Though the efficacy of mood-alleviating treatments 
for VMS would suggest that mood precipitates VMS, the mood-independent efficacy of 
treatment tend to offer more support to the third factor theory than to either theory of temporal 
relationship.  The theory that mood precedes VMS is supported by some epidemiological and 
ambulatory data, suggesting that both stable affect and short-term, acute mood states may 
influence VMS presentation.  There is also limited evidence from diary studies that VMS 
precedes mood when both are measured on a daily basis.    
Table 3.  Temporal relationships 
Author 
(year) 
Sample Subject VMS measure Affect measure Outcome of 
interest 
Directionality 
of effect 
Treatment studies 
Gordon 
(2006) 
N=102 
Age=40-65 
Sample=Healthy 
women with VMS 
Timeframe=4 weeks 
Sertraline for the 
treatment of VMS 
VMS presence/severity self-
reported in daily diary 
Depressive symptoms 
(Medical Outcomes Study) 
at baseline and week 4 
VMS 
reduction 
3rd factor 
>VMS, mood? 
Joffe 
(2007) 
N=20 
Age=40-60 
Sample= Depressed 
women with frequent 
VMS 
Timeframe=8 weeks 
Duloxetine for the 
treatment of depression 
and VMS in depressed 
women 
VMS presence/severity self-
reported with the Greene 
Climacteric Scale vasomotor 
subscale at two and eight 
weeks 
Depressive symptoms 
(Montgomery-Asberg 
Depression Rating Scale), 
anxiety (Beck Anxiety 
Inventory) at two and eight 
weeks 
VMS and 
depressive 
symptom 
reduction 
3rd factor 
>VMS, mood? 
Ladd 
(2005) 
N=16 
Age=42-51 
Sample= Depressed 
perimenopausal 
women 
Timeframe=8 weeks 
Venlaxafine for the 
treatment of depression 
and VMS in depressed 
women 
VMS presence/severity self-
reported with the Greene 
Climacteric Scale vasomotor 
subscale at two and eight 
weeks 
Depressive symptoms 
(Hamilton Rating Scales for 
Depression), anxiety 
(Hamilton Rating Scales for 
Anxiety) 
VMS and 
depressive 
symptom 
reduction 
3rd factor 
>VMS, mood? 
Schmidt 
(2000) 
N=34 
Age=44-55 
Sample=Depressed 
women with and 
without VMS 
Timeframe=6 weeks 
Hormone therapy for the 
treatment of 
perimenopausal 
depression in women 
with and without VMS 
VMS presence as self-
reported in daily diaries 
during screening phase 
Depressive symptoms 
(CES-D, Ham-D) 
Depressed 
mood 
3rd factor 
>VMS, mood? 
Soares 
(2006) 
N=40 
Age=40-60 
Sample=Depressed 
women with frequent 
VMS 
Timeframe=8 months 
Hormone therapy v. 
escitalopram for the 
treatment of VMS and 
depression 
VMS presence/severity self-
reported with the Greene 
Climacteric Scale vasomotor 
subscale at two, four, and 
eight weeks 
Depressive symptoms 
(Montgomery-Asberg 
Depression Rating Scale) 
VMS and 
depressive 
symptom 
reduction 
3rd factor 
>VMS, mood? 
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Table 3 (Continued) 
 
Suvanto-
Luukkonen 
(2005) 
N=150 
Age=45-66 
Sample=Healthy 
postmenopausal women with 
VMS (Finland) 
Timeframe=9 months 
Citalopram and fluoxetine 
for the treatment of VMS 
in non-depressed women 
VMS frequency self-
reported in daily diary for 
9 months 
Depressive symptoms 
(Beck Depression 
Inventory) 
VMS 
reduction 
3rd factor 
>VMS, 
mood?  
 
Epidemiological studies 
Dennerstein 
(2004) 
N=438 
Age=45-55 
Sample=MWMHP 
(Australia) 
Timeframe=11 years 
Predictors of depressed 
mood in menopause 
Self-reported bothersome 
VMS in previous 2 weeks 
Depressive 
sympotoms (CES-D) 
Depressed 
mood 
VMS > 
Mood 
Freeman 
(2009) 
N=170 
Age=35-47 
Sample=Penn Ovarian Aging 
Study 
Timeframe=10 years 
VMS and depressed mood 
in menopause 
VMS occurrence, 
frequency, and severity in 
previous month 
Depressed mood 
(CES-D) 
VMS, 
depressed 
mood  
Mood > 
VMS 
Freeman 
(2005) 
N=436 
Age=35-47 
Sample=Penn Ovarian Aging 
Study 
Timeframe=6 years 
Anxiety and hormonal 
changes as predictors of 
VMS 
VMS occurrence, 
frequency, and severity in 
previous month 
Anxiety (Zung 
Anxiety Index) 
VMS Mood > 
VMS  
Freeman 
(2001) 
N=375 
Age=35-47 
Sample=Penn Ovarian Aging 
Study 
Timeframe=9 months 
Predictors of VMS in late 
reproductive years 
 
VMS occurrence, 
frequency, and severity in 
previous month 
Anxiety (Zung 
Anxiety Index) 
VMS Mood > 
VMS 
Guthrie (2005) N=350 
Age=45-55 
Sample=Melbourne 
Women’s Midlife Health 
Project (MWMHP) 
Timeframe=9 years 
Predictors of VMS 
presence, severity, and 
frequency 
Self-reported severity and 
frequency of bothersome 
VMS in previous 2 weeks 
Negative moods 
(Affectometer-2 
subscale) 
VMS Mood > 
VMS 
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Sabia 
(2008) 
N=28,118 
Age=50-75 
Sample=  French E3N 
Timeframe=biannual 
questionnaires over 10 
years 
Risk factors for onset 
of menopausal 
symptoms 
Self-reported occurrence of 
menopausal symptoms (list of 
5, including VMS) 
History of depression at 
baseline (self-report) 
VMS (among 
other 
menopausal 
symptoms) 
Mood 
> 
VMS 
Ambulatory and daily diary studies 
Burleson 
(2010) 
N=55 
Age=42-52 
Sample=healthy volunteers 
Timeframe=36 contiguous 
weeks within 5 years of 
data collection 
SEM model testing 
direct effects of VMS 
on mood and indirect 
effect via sleep 
disruption 
Self-reported VMS occurrence 
and frequency self-reported in 
daily diaries for up to 5 years 
(36 contiguous weeks used in 
analyses) 
Negative mood (mean 
composite score from daily 
diary checklist:  anxious, 
depressed, distressed, 
nervous, hostile, ashamed, 
guilty, irritable) 
Negative mood VMS 
> 
mood  
  
Thurston 
(2005) 
N=42 
Age=40-60 
Sample=peri- and 
postmenopausal women 
with VMS 
Timeframe=Two 
noncontiguous 24 hour 
periods 
Emotional antecedents 
of VMS 
 Self-reported VMS as 
occurring (behavioral diary, 
event marker), physiologically 
measured VMS (sternal skin 
conductance) 
Depressive symptoms, state 
anxiety, trait anxiety 
VMS Mood 
> 
VMS 
Woods 
(1997) 
n=337 
age=35-47 
Sample=Seattle Midlife 
Women’s Health Study 
Timeframe=5 days 
Depressed mood in the 
menopausal transition 
VMS occurrence and severity 
self-reported in daily diaries for 
5 days 
Depressed mood (CES-D, 
SCL-90) 
Depressed 
mood 
Not 
seen 
 
2.5.4 Summary of current literature 
Vasomotor symptoms are common in the menopausal transition, and are linked to decreased 
quality of life and declining health status.  However, the frequency, severity, duration, and 
perception of these common events are highly variable.  The mechanisms behind these events 
and reasons for their variable presentation are not well understood.  Measures of negative affect 
are consistently associated with self-reported VMS when both are measured concurrently or at 
one point in time relative to another, though the nature of this relationship is not currently 
understood.  This relationship seems to be strongest in perimenopausal women and with 
measures of anxiety, and is not always seen in non-perimenopausal women or women with 
diagnosed depression. Negative mood may precipitate VMS, a theory which is supported by 
ambulatory measurement of self-reported mood and VMS and findings from longitudinal 
analyses comparing the onset of VMS to the onset of anxious and depressive symptoms over the 
menopausal transition.  It is also possible that VMS instead precipitates negative mood, which is 
assumed in studies attributing an increase in negative mood over the menopausal transition to an 
increase in VMS, and supported by one investigation into VMS as a daily precursor to negative 
mood.  Alternatively, a third, unmeasured factor may underlie both mood and VMS.  This 
perspective may be supported by treatment studies, in which interventions typically used to treat 
mood also effectively treat VMS, without strong evidence that the treatment effect is acting via 
mood changes.   
 25 
2.5.5 Limitations of the current literature addressed in study 
Interpretation of the relationship between affect and VMS is currently limited by potentially 
biased retrospective recall of VMS, infrequent measurement of VMS and affect, and limited 
investigations into the temporal relationship between these factors.  Cross-sectional studies 
provide information about the association between affect and VMS, but interpretation of the 
association is difficult and could be due to any possible pathway between or underlying these 
factors.  Affect and VMS are assessed only at one point in time, and may not represent stable 
patterns.  Further, VMS in these studies are largely reported by retrospective recall; the 
association between negative affect and VMS may be due to recall biased by affect at the time of 
reporting (Thurston, 2005).  Longitudinal studies offer more robust evidence of the association 
over time, but are also subject to the third factor issue and potentially biased VMS reporting 
based on the same retrospective recall methods.  While longitudinal studies can be utilized to 
help elucidate the directionality of the association between affect and VMS, few have 
purposefully done so.   
The proposed study will attempt to address these limitations.  Interpretation of 
associations seen in the current literature, based largely on findings from one-time and annual 
assessments, will be expanded by utilizing novel data collection to assess acute associations 
between measures of negative affect and VMS over time.  Daily prospective measures of mood 
and VMS will limit the potential bias of retrospective recall while allowing examination of 
temporal relationships on a day-to-day basis between factors.  While this is not the first study to 
specifically look at acute changes in affect or VMS in relation to the other with prospective diary 
data, the few existing studies are hampered by small sample sizes, short observation periods, 
statistical conclusions biased by a priori assumptions, no consideration of woman-level 
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covariates, and observation during periods of limited symptom experience.  In contrast, the 
proposed study will utilize a large, ethnically diverse sample followed over several weeks, 
resulting in over 21,000 observations.  This primarily perimenopausal sample is expected to have 
a high level of VMS as well as negative mood symptoms, and represent the cohort most likely to 
exhibit a relationship between these factors.   While a priori hypotheses regarding the temporal 
associations between VMS and affect will be made, bidirectional relationships will be tested and 
reported.     
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3.0 SPECIFIC AIMS 
Using the daily diaries of the SWAN Daily Hormone Study (DHS), prospectively recorded affect 
and vasomotor symptoms among women in the menopausal transition was examined to evaluate 
the day-to-day associations between negative affect and VMS over the course of one menstrual 
cycle or comparable period, with a breadth of contributing factors taken into account.  The 
temporal relationship between day-to-day affect and VMS occurrence was evaluated.  The use of 
prospective daily diary data limited the retrospective bias inherent in most existing studies of 
VMS.   
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4.0 HYPOTHESES 
VMS and measures of negative affect are generally associated in cross-sectional and longitudinal 
measurements of both factors.  To that end, we expected to replicate this relationship in this 
sample, with daily measurements of VMS and affect across a menstrual cycle among women in 
midlife.   
H1:  Negative affect in a given 24-hour period will be associated with vasomotor 
symptoms in that same 24-hour period over the course of a menstrual cycle or comparable 
period. 
 Negative affect may impact the subjective experience of symptoms, influencing 
symptom perception via increased cognitive catastrophization, vigilance to somatic symptoms, or 
anxiety sensitivity, creating an environment in which symptoms are more commonly perceived 
and reported (Hannisch, 2008; Thurston, 2008a).  Negative emotional arousal and stress may 
serve as an acute trigger for VMS, which has been anecdotally reported and supported by 
ambulatory measurement of self-reported symptoms (Thurston, 2005).  This influence of mood 
on subjective experience is further suggested by the association of negative mood with self-
reported, but not objectively measured VMS, the strong effect of placebo treatment on self-
reported symptoms, and the influence of negative affect on subjective characteristics of 
experience such as symptom bother (Thurston, 2008a).  This relationship has also been 
supported by analyses indicating that anxiety (Freeman, 2005) and depressive symptoms 
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(Freeman, 2009), precede the onset of self-reported VMS.  Therefore, we hypothesized that 
mood would precede VMS.  
H2:  Negative affect in a given 24-hour period will be associated with vasomotor 
symptoms in the subseqent 24-hour period adjusting for VMS in the prior 24 hours  over the 
course of a menstrual cycle or comparable interval . 
 While perimenopausal depression and an increase in negative mood over the 
menopausal transition are often attributed to increased VMS (Keefer, 2005), this relationship is 
not always seen when explicitly tested.  Further, the lack of a relationship between objective 
measures of VMS and negative mood implies that mood influences symptom perception rather 
than that symptoms themselves precipitate mood.  Therefore, we hypothesized that VMS would 
not precede mood in this sample. 
H3:  Vasomotor symptoms in a given 24-hour period will not be associated with 
negative affect in the subsequent 24-hour over the course of a menstrual cycle or comparable 
period. 
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5.0 STUDY IMPLICATIONS 
Better understanding the relationship between negative mood and VMS may help elucidate the 
mechanisms underlying VMS, influencing intervention strategies for women in the menopausal 
transition.  Examining this relationship in a daily fashion also provided the opportunity to 
uncover potential shortcomings or biases in typical measurement.       
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6.0 METHODS 
6.1     PARTICIPANTS 
The Study of Women's Health across the Nation (SWAN) is a multiethnic, community-based 
natural history cohort study of 3,302 women at seven sites across the United States followed 
annually as they approach and traverse the menopause. The details of recruitment and enrollment 
have been reported elsewhere in detail (Sowers, 2000). Briefly, eligible women were, at baseline, 
aged 42–52 years, self-identified with one of five racial/ethnic groups (Caucasian, African-
American, Chinese, Japanese, or Hispanic), reported at least one menstrual period in the prior 3 
months, did not use sex-steroid hormones in the prior 3 months, had an intact uterus and at least 
one ovary, and were not currently pregnant or breastfeeding (Skurnick, 2009).  SWAN is a 
unique study in its large sample size, geographic distribution, and multiethnic composition.  The 
ability to follow this number of women over the course of the menopausal transition has 
enhanced our understanding of the physical and emotional symptoms and experiences of 
menopause.  By following this diverse population over time, we are able to advance our 
knowledge of the menopause in women overall and in specific, understudied populations. 
Of the 3,302 women in the SWAN cohort, 1,443 were screened for Daily Hormone Study 
(DHS) eligibility. Inclusion criteria for recruitment into the DHS were: 1) an intact uterus and at 
least one ovary, 2) at least one menstrual period in the previous 3 months, 3) no use of sex steroid 
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hormones in the previous 3 months, and 4) not pregnant.  Of the 1,219 eligible women invited to 
complete the baseline urine collection, 848 (69.6%) women agreed to participate and provided a 
sufficiently complete cycle for analysis.  The present analysis used the third year of DHS (DHS 
3), which includes 651 of the original 848 women. Reasons for discontinuation or non-
participation in DHS 3 included current or recent (within the previous 3 months) HT use (n=65), 
fertility medication use (n=1), and oral contraceptive use (n=3), bilateral oopherectomy (n=7), 
more than one year of amenorrhea (n=7) (women were eligible in the first year of becoming 
postmenopausal), refusal or inability to participate in that year’s DHS visit (n=40), and attrition 
from SWAN (n=74).  Women who had a hysterectomy were eligible as long as they retained one 
or both ovaries.  More information on the details of data collection based on different eligibility 
parameters is available in figure 1.  SWAN DHS maintains the diversity of the larger SWAN 
cohort, while adding knowledge of the day-to-day experience of menopause and hormonal 
changes to the information gained in annually collected measures.  DHS 3 was chosen as the 
analytic sample because it is comprised of a larger percentage of perimenopausal women (80%) 
than other available years.  We therefore expected the greatest frequency of VMS (Gold, 2006) 
and negative mood (Bromberger, 2010), and the strongest association between VMS and mood 
(Seritan, 2009), in this over other available samples.   
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Rollover 
Pregnancy or HT, fertility meds, OC 
 
25 day collection 
Amenorrhea for 12+ months 
Discontinue 
BSO, refusal, attrition 
 
Cycle collection 
Menses in previous 3 months 
Collect for duration of cycle, or 50 days if 
50 day collection 
Hysterectomy or >3,  
<12 months amenorrhea 
 
DHS (n=828) 
 
SWAN (n=3,302) 
 
 
Figure 1.  Daily Hormone Study Schematic 
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6.2     PROCEDURE 
DHS enrollees completed a daily diary in which they recorded experience of any vasomotor 
symptoms within the preceding 24 hours for an entire menstrual cycle ending in bleeding or 50 
days, whichever came first. Women who did not have a bleeding cycle coincident with 1-year 
follow-up began on the next convenient day and collected for 50 days or until a menstrual cycle 
began. Women who had no menses for the 12 months before an annual follow-up kept a daily 
diary for 25 days (Skurnick, 2009).  Parameters for data collection are detailed in figure 1. 
6.3 MEASURES 
6.3.1 Outcomes  
6.3.1.1  Diary overview  Participants in DHS were asked to complete a daily diary every 
evening before bed for the duration of the study.  The diary was one page long, with 14 feelings 
and physical states (happy, bored, headaches, blue/down, tired, aches/pains, calm, forgetful, 
mood swings, irritable, anxious, confident/in control, difficulty concentrating, feelings easily 
hurt) listed along with three yes/no questions about other symptoms.  A 1-4 scale was listed 
beside each item (1=not at all, 2=a little bit, 3=moderately, 4=a lot).  Before bed, participants 
were asked to mentally review their day and record how strongly they felt each item during the 
previous 24 hours. A sample diary is depicted in figure 2.   
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Figure 2.  Daily Hormone Study Daily Diary 
(underlined text from codebook, not included in participant version) 
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6.3.1.2  Vasomotor symptoms  A single question in the daily diary asked if participants had 
experienced hot flashes/night sweats in the previous 24 hours.  A binary variable was created 
from these yes/no responses. 
6.3.1.3  Measure of negative affect  A principal components analysis (PCA) was conducted 
with oblique rotation in SPSS (SPSS, 2008) on the 14 items of the daily diary.  Because the 
number of observations differed between women in this sample, the PCA was run with data from 
only the first twelve observations, the minimum number of observations available for all 
participants. PCA revealed the presence of three components with eigenvalues exceeding 1. The 
relatively high correlations between factors and comparison of the pattern and structure matrix 
suggested that oblique rotation was most appropriate for this data.   
The first component was comprised of seven variables related to negative mood:  mood 
swings, feelings easily hurt, irritable, difficulty concentrating, forgetful, anxious, and blue/down, 
with factor loadings ranging from .53 (blue/down) to .85 (mood swings) (Tables 4, 5). This 
component explained 39.0% of the variance and had a Cronbach’s alpha of .87.  These items 
were summed, and a mean score calculated for each daily observation.  This daily negative mood 
variable was dichotomized due to its non-normal distribution, with scores ≥2 indicating the 
presence of negative mood.  For the purposes of preliminary analysis, the overall mean negative 
mood score across all observations for each participant was also calculated, and also 
dichotomized with scores ≥2 indicating the presence of higher overall negative mood. 
6.3.1.4  Measure of positive affect  A positive affect variable was drawn from the second factor 
of the PCA, comprised of 3 items:  confident/in control, happy, and calm.  This item explained 
10.2% of the variance, and has a Cronbach’s alpha of .77.  Daily and overall mean composite 
positive mood variables were created for each participant, and treated as continuous variables. 
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Table 4.  Principal Component Analaysis Pattern Matrix 
 Component 
 1 2 3 
Past 24h-mood swings .851   
Past 24h-feelings easily hurt .838   
Past 24h-irritable .741   
Past 24h-anxious .653   
Past 24h-difficulty concentrating .649   
Past 24h-forgetful .595   
Past 24h-blue/down .534   
Past 24h-bored .338   
Past 24h-confident/in control  .807  
Past 24h-calm  .775  
Past 24h-happy  .765  
Past 24h-aches/pain   -.821
Past 24h-headaches   -.685
Past 24h-tired   -.664
Extraction Method: Principal Component Analysis.  
 Rotation Method: Oblimin with Kaiser Normalization. 
a. Rotation converged in 6 iterations. 
 
Table 5.  Principal Components Analaysis Structure Matrix 
 Component 
 1 2 3 
Past 24h-mood swings .823 -.347  
Past 24h-irritable .779 -.371 -.360
Past 24h-feelings easily hurt .766 -.308  
Past 24h-difficulty concentrating .710  -.460
Past 24h-anxious .689 -.426  
Past 24h-blue/down .684 -.531 -.349
Past 24h-forgetful .603  -.425
Past 24h-bored .419   
Past 24h-confident/in control -.377 .825  
Past 24h-happy -.371 .788  
Past 24h-calm -.352 .787  
Past 24h-aches/pain .305  -.803
Past 24h-tired .409 -.314 -.723
Past 24h-headaches .312  -.695
Extraction Method: Principal Component Analysis.  
 Rotation Method: Oblimin with Kaiser Normalization. 
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6.3.2 Covariates 
 Potential covariates were selected due to their associations with VMS and negative mood in the 
literature. Covariates considered were site, age, education, and race, drawn from baseline, and 
physical activity, self-rated health, BMI, smoking, menopausal status, and antidepressant use, 
assessed anually and drawn for this analysis from the annual SWAN visit preceding and most 
proximal to DHS 3 data collection. The coordinating SWAN site of each participant was 
recorded.  Age was calculated using date of birth and the date of the first day of DHS 3 data 
collection.  Education and race/ethnicity were self-reported at SWAN baseline.   Education, a 
proxy for socioeconomic status, was determined using one question that asks the highest grade 
completed or degree attained (Centers for Disease Control and Prevention, 1994), and coded as 
“less than high school”, “high school graduate”, “some college”, “college graduate”, and “post-
college”. Race/ethnicity was self-determined by study participants and was obtained by asking 
the following open-ended question: “How would you describe your primary racial or ethnic 
group?” The responses were categorized as Caucasian (white), African American, Chinese, 
Japanese, or Hispanic.  Physical activity was assessed at baseline and at annual follow-up visits 
3, 5, and 6 with the Kaiser Physical Activity Survey (KPAS) (Sternfeld, 1999), an adaptation of 
the Baecke physical activity questionnaire (Baecke, 1982).  Self-rated health was assessed by 
response to the following question:  “In general, would you say your health is excellent, very 
good, good, fair or poor?”. Responses were categorized into four categories, with responses of 
“fair” and “poor” collapsed into a single category.  Body mass index (BMI) was calculated using 
weight (kg) and height (m)2.  This variable was also categorized (underweight/normal:  <25; 
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overweight:  25-30; obese:  >30) for descriptive analysis.  Smoking status (never, ever, current) 
was self-reported at each visit.  Menopausal status was assessed annually in SWAN and was 
defined as indeterminant (pre- and perimenopasual women who used hormones in the past year), 
premenopausal (bleeding in the last 3 months with no cycle irregularity in the previous 12 
months), early perimenopausal (bleeding in the last 3 months with some change in cycle 
regularity in the last 12 months), late perimenopausal (bleeding >3 months ago but within the last 
12 months), postmenopausal (no bleeding in the last 12 months).   Menopausal status was 
collapsed into three categories:  premenopausal, perimenopausal (early and late perimenopausal), 
and postmenopausal.  For this analysis, records were reviewed to reclassify women defined as 
indeterminant as premenopausal (n=1) or perimenopausal (n=9), based on their status at annual 
visits before and after the annual visit coinciding with DHS 3. Current antidepressant use was 
self-reported in response to questions about medications used currently and in the previous year 
during each annual SWAN visit.   
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7.0 ANALYTIC PLAN 
7.1     DATA SOURCE 
For all analyses, daily-level variables (VMS, mood) were drawn from the daily diaries of DHS 3, 
and woman-level covariates were drawn from the annual SWAN follow-up visit closest to the 
DHS visit date for each participant.   
7.2     PRELIMINARY ANALYSES 
We identified and addressed outliers, examined the distribution of study variables, and 
categorized variables as needed.  Differences in key factors between those women who ever 
reported vasomotor symptoms over the observed time period and those who did not, and between 
those women with overall average negative mood ≥2 or <2, were assessed using logistic 
regression.  Associations between key factors and overall positive mood were assessed with 
linear regression.  Descriptive analysis was conducted to evaluate the overall proportions of days 
that women experienced mood and vasomotor symptoms over the observed period.  Analyses 
were conducted with SPSS v. 17 (SPSS, 2008). 
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       7.3     PRIMARY ANALYSES 
Daily observations, nested within women, were examined with two-level hierarchical 
generalized linear models (HGLM).  Analyses were conducted with HLM 6.08 (HLM, 2009).  
To address the first hypothesis, daily negative affect was regressed on same day VMS; in 
separate models, daily VMS was regressed on same day negative affect.  To address the second 
and third hypotheses, regarding the temporal association between affect and VMS, a lagged 
analysis was utilized.  Specifically, negative affect at time t, adjusted by vasomotor symptoms at 
time t, was examined as a predictor of vasomotor symptoms at time t+1; vasomotor symptoms at 
time t, adjusted by negative affect at time t, was examined as a predictor of negative affect at 
time t+1. Woman-level covariates were regressed on the daily-level intercept in adjusted models.  
Regression equations are detailed in appendix 3. 
The final models used to address study hypotheses were determined as follows, with 
equations again detailed in appendix 3.  Intercepts-only models were run to determine the 
variance in each level present for each daily outcome, and to verify that random intercepts were 
appropriate for these models. Associations between daily predictors and daily outcomes were 
assessed with random-coefficients models.  In order to determine whether expected daily 
outcomes varied as a function of participant characteristics, associations between potential 
woman-level covariates and each daily outcome were determined individually with means-as-
outcomes models.  Covariates were retained in final models if they exhibited significant 
associations with the daily outcome, p<.20, and those included in fully adjusted final models 
therefore varied by outcome.  The intercept for all analyses was modelled as a function of 
race/ethnicity, menopausal status, self-rated health, and age.  Education was included in models 
with VMS as the outcome; antidepressant use was included in models with negative mood as the 
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outcome. Age was grand-centered around the sample mean of 48.8; all other variables were 
uncentered.  Site was not considered as a covariate for daily outcomes, due to the confounded 
relationship between race/ethnicity and site in SWAN.  In order to determine whether the 
relationship between mood and VMS varied as a function of participant characteristics, slopes-
and-intercepts as outcomes models were used to test for potential cross-level interactions.  Due 
to the differences in VMS reporting by race/ethnicity, menopausal status, and BMI suggested in 
the literature, as well as the possible moderating effect of menopausal status on the relationship 
between mood and VMS suggested by some studies, these covariates were of particular interest.  
No significant cross-level interactions were seen, and no interaction terms were entered into the 
final models.  
Outcomes for all models were set as a Bernoulli distribution, indicating that for each 
daily observation, an outcome of 0 (absent) or 1 (present) was possible.  Outcomes were also 
corrected for overdispersion. Restricted maximum likelihood estimation was utilized for all 
models, and unit-specific models with robust standard errors were interpreted.  A random 
intercept was postulated for all models.  Random slopes best fit the data and were retained for all 
models, after confirming that the random effects of variance components was significant at p 
<.05, and that standard errors and robust standard errors were closer in random than fixed effects 
models. 
7.4     SECONDARY ANALYSES 
In order to evaluate whether positive mood has a differential association with VMS, all models 
were re-run with positive mood in place of negative mood.  These were run with 2-level HLM, 
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as positive mood was assumed to follow a normal distribution.  Significant covariates included in 
adjusted models were education, race/ethnicity, menopausal status, self-rated health, and age. 
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8.0 RESULTS 
8.1     CHARACTERISTICS OF SAMPLE 
The final sample was comprised of 625 women.  Sample characteristics of the sample are 
detailed in table 4.  Participants completed daily diaries over a period of 12-50 days (mean 33.91, 
SD 10.85), and were excluded from analysis if they were missing information daily diary data on 
all observations (n=26).  Women who were excluded were more likely to be from the New 
Jersey site (p<.01), to be Hispanic (p<.01), to have a high school education or less (p<.01), to 
report fair/poor self-rated health (p=.02), and to have a higher BMI (p=.02) than women included 
in the final analytic sample (data not shown).  
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Table 6.  Characteristics of sample:  Between-women study variables  
 Total 
(n=625) 
n, column % 
Site  
Michigan 11 63 (10.1) 
Boston 12 68 (10.9) 
Chicago 13 68 (10.9) 
UC-Davis 14 175 (28.0) 
UCLA 15 143 (22.9) 
New Jersey 16 46 (7.4) 
Pittsburgh 17 62 (9.9) 
Race/ethnicity  
Black 123 (19.7) 
White 191 (30.6) 
Chinese 122 (19.5) 
Hispanic 46 (7.4) 
Japanese 143 (22.9) 
Education  
College/post-college To 
Some college 198 (31.9) 
High school/<hs 145 (23.3) 
Self-rated health  
Excellent 100 (16.2) 
Very good 238 (38.4) 
Good 208 (33.6) 
Fair/poor 73 (11.8) 
Categorical BMI  
Normal/underweight (<=24.9) 269 (43.5) 
Overweight (25-30) 162 (26.2) 
Obese (>30) 187 (30.3) 
Smoking status  
Current smoker 57 (9.2) 
Current non-smoker 563 (90.8) 
Menopausal status  
Postmenopausal 30 (4.8) 
Perimenopausal 510 (81.6) 
Premenopausal 84 (13.4) 
Antidepressant use   
Yes 60 (9.6) 
No 565 (90.4) 
VMS  
Yes 327 (52.3) 
No 298 (47.7) 
  
 Mean, SD 
BMI 27.73 (6.77) 
Age 48.80 (2.51) 
Physical activity  7.69 (1.73) 
Negative mood  1.66 (.57) 
Positive mood  2.86 (.64) 
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Over the observed period, 52.3% of participants (n=327) ever reported VMS.  Ever 
reporting VMS was less common in Chinese women, but did not otherwise vary significantly by 
race (table 5).  Ever reporting VMS was more common in older women, perimenopausal women, 
among women with poorer self-rated health, and among women at the Michigan, Boston, and 
Chicago SWAN sites compared to the Pittsburgh site (table 5).  Ever reporting VMS was 
associated with higher mean negative mood and lower mean positive mood over the course of 
the daily diary collection.   
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Table 7.  Univariate relationships between study variables and ever reporting VMS during daily diary 
collection 
 
 Odds Ratio 95% CI p-value 
Site   .01 
Michigan 11 2.11 1.03-4.30 .04 
Boston 12 2.38 1.12-4.82 .02 
Chicago 13 2.90 1.42-5.92 <.01 
UC-Davis 14 1.19 .66-2.14 .55 
UCLA 15 1.33 .73-2.4 .36 
New Jersey 16 1.39 .64-2.98 .41 
Pittsburgh 17 -- -- -- 
Race/ethnicity   .02 
White -- -- -- 
Black 1.05 .66-1.67 .83 
Chinese .50 .32-.79 <.01 
Hispanic .72 .45-1.37 .72 
Japanese .69 .45-1.07 .69 
Education   .24 
College/post-college -- -- -- 
Some college 1.42 .95-2.13 .09 
High school/<hs 1.14 .79-1.64 .49 
Self-rated health   .03 
Excellent -- -- -- 
Very good 1.16 .73-1.86 .53 
Good 1.48 .92-2.39 .11 
Fair/poor 2.35 1.26-4.38 .01 
BMI 1.02 .99-1.04 .15 
Categorical BMI   .65 
Normal/underweight (<=24.9) -- -- -- 
Overweight (25-30) 1.17 .79-1.73 .43 
Obese (>30) 1.16 .80-1.68 .44 
Smoking status .94 .55-1.62 .83 
Menopausal status   <.01 
Postmenopausal 2.00 .86-4.67 .11 
Perimenopausal 2.51 1.55-4.09 <.001 
Premenopausal -- -- -- 
Antidepressant use  1.53 .88-2.63 .13 
Age 1.07 1.00-1.14 .04 
Physical activity  1.02 .93-1.12 .74 
Overall negative mood  1.79 1.30-2.45 <.001 
Overall positive mood  .68 .52-.90 <.01 
All variables entered independently into logistic regression models. 
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Over 15% of participants (n=96) had an overall mean negative mood score ≥2.  Overall 
negative mood (≥2) was associated with poorer health, perimenopausal status, site, and 
race/ethnicity, with women from the New Jersey SWAN site and Hispanic women exhibiting 
higher average negative mood scores than their counterparts.  Similarly, less education, poorer 
health, and perimenopausal status were associated with decreased overall average positive mood.  
Positive mood also varied by race/ethnicity, with decreased average positive mood seen among 
Hispanic women.  Higher average positive mood was associated with increased levels of self-
reported physical activity (table 6).   
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Table 8.  Univariate relationships between study variables and overall mean negative mood (≥ 2), positive 
mood  
 
Negative mood (≥ 2) Positive mood  
Odds Ratio 95% CI p-value Beta Coefficient 95% CI p-value 
Site   .13   <.01 
Michigan 11 1.36 .44-4.17 .59 .09 -.03-.34 .10 
Boston 12 1.07 .40-3.38 .91 -.02 -.21-.15 .75 
Chicago 13 1.61 .55-4.72 .39 .07 -.07-.29 .23 
UC-Davis 14 1.48 .58-3.82 .41 .05 -.09-.21 .44 
UCLA 15 2.37 .93-6.05 .07 -.03 -.19-.12 .68 
New Jersey 16 3.29 1.13-9.59 .03 .-10 -.41-.00 .05 
Pittsburgh 17 -- -- -- -- -- -- 
Race/ethnicity   .03   <.01 
White -- -- -- -- -- -- 
Black .75 .36-1.57 .45 .08 -.01-.23 .08 
Chinese 1.28 .67-2.46 .45 -.03 -.16-.08 .54 
Hispanic 2.46 1.12-5.38 .03 -.12 -.41--.08 .01 
Japanese 1.77 .98-3.20 .06 -.06 -.19-.04 .21 
Education   .44   <.01 
College/post-college -- -- -- -- -- -- 
Some college .89 .53-1.50 .65 -.03 -.13-.07 .56 
High school/<hs 1.29 .76-2.19 .35 -.14 -.28--.07 <.01 
Self-rated health   <.001   <.001 
Excellent -- -- -- -- -- -- 
Very good 1.77 .75-4.20 .19 -.21 -.33--.09 <01 
Good 2.88 1.23-6.70 .01 -.40 -.52--.28 <.001 
Fair/poor 6.11 2.45-15.23 <.001 -.57 -.72--.42 <.001 
BMI 1.01 .97-1.04 .73 -.03 -.01-.00 .44 
Categorical BMI   .20   .56 
Normal/underweight (<=24.9) -- -- -- -- -- -- 
Overweight (25-30) 1.50 .89-2.51 .13 -.01 -.11-.10 .89 
Obese (>30) .94 .55-1.62 .82 -.05 -.15-.05 .30 
Smoking status .77 .34-1.75 .53 -.02 -.18-.11 .59 
Menopausal status   .03   <.01 
Postmenopausal  1.76 .39-7.84 .46 .05 -.10-.34 .30 
Perimenopausal 3.30 1.30-8.37 .01 -.10 -.26--.02 .02 
Premenopausal  -- -- -- -- -- -- 
Antidepressant use  1.79 .94-3.41 .08 -.06 -.25-.03 .12 
Age .97 .89-1.06 .52 .04 -.01-.02 .37 
Physical activity  .94 .83-1.07 .35 .11 .01-.06 <.01 
All variables entered independently into logistic (negative mood) and linear (positive mood) regression models. 
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8.1.1 Daily diary:  VMS 
Symptomatic women reported VMS on 2-100% of daily observations.   Overall, and among all 
groups but Hispanic women, most participants with VMS reported symptoms on 2-30% of days 
collected (data not shown).  Most of the variance (95%) in VMS reporting was seen between 
women, with 5% of the variance occurring within women’s daily observations (table 7).  
Significant woman-level predictors of daily VMS were similar to the significant predictors of 
ever reporting VMS reported in the previous section (table 8).   
8.1.2 Daily diary:  Mood 
Most of the variance (96%) in negative mood reporting was seen between women, with 4% of 
the variance occurring within women’s daily observations (table 7).  Daily negative mood (≥2) 
was reported on 20% of observations (n=4194) (data not shown).  Significant woman-level 
predictors of daily negative mood (≥2) were similar to those associated with overall negative 
mood (table 8). The expected unadjusted positive mood score was 2.88 (SE .02) on a 1-4 scale.  
Most of the variance (64%) in positive mood reporting was seen between women, with 36% of 
the variance occurring within women’s daily observations.  Significant woman-level predictors 
of daily positive mood were similar to those associated with overall positive mood (data not 
shown). 
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Table 9:  Between- and within-woman variance for daily within-woman outcomes:  Daily VMS, daily negative 
mood, daily positive mood 
 
 VMS Negative mood Positive mood 
Between  95% 96% 64% 
Within 5% 4% 36% 
 
Table 10:  Unadjusted associations of between-women covariates and daily within-woman daily VMS and 
daily negative mood 
 
Between-women 
covariates 
Intercept 
(VMS) 
OR (95% 
CI) 
Association with 
VMS 
OR (95% CI) 
p-
value 
Intercept 
(negative 
mood) 
OR (95% CI) 
Association with 
negative mood 
OR (95% CI) 
p-value 
Age .05 (.04-.06) 1.18 (1.07-1.31) <.01 .07 (.06-.09) 0.90 (0.82-0.99) .03 
Antidepressant use .05 (.04-.06) 1.50 (0.66-3.40) .33 .06 (.05-.08) 3.48 (1.51-8.05) <.01 
BMI .05 (.04-.06) 1.03 (.99-1.07) .20 .07 (.05-.09) 1.92 (.99-1.06) .27 
BMI (cat) .04 (.03-.07)   .06 (.04-.08)   
Normal/underweight  Ref   Ref  
Overweight  .91 (.49-1.70)    .76  1.55 (.83-2.87) .17 
Obese  1.38 (.73-2.62) .32  1.35 (.76-2.38) .30 
Education .03 (.02-.05)   .07 (.05-.11)   
High School or less  2.12  (1.13-4.01) .02  1.06 (.55-2.06) .86 
Some College  2.03 (1.10-3.75) .03  .76 (.44-1.33) .34 
College +  Ref   Ref  
Menopausal status .01 (.01-.03)   .03 (.02-.05)   
Postmenopausal  9.19 (1.89-44.67) .02  .41 (.11-1.54) .22 
Perimenopausal  4.19 (2.05-8.58) <.01  3.13 (1.65-5.92) <.01 
Premenopausal  Ref   Ref  
Health .04 (.02-.08)   .02 (.01-.04)   
Excellent  Ref   Ref  
Very Good  .87 (.39-1.93) .73  2.32 (1.19-4.53) .01 
Good  1.48 (.66-3.68) .34  4.02 (1.97-8.19) <.001 
Fair/poor  4.54 (1.57-13.14 .01  13.42 (5.38-
33.46) 
<.001 
Race/ethnicity .06 (.04-.09)   .08 (.05-.12)   
White  Ref   Ref  
Black  1.24 (.60-2.57) .56  .42 (.20-.86) .01 
Chinese  .33 (.16-.67) <.01  .81 (.40-1.63) .55 
Hispanic  1.13 (.32-4.01) .85  3.56 (1.26-10.10) .03 
Japanese  .75 (.37-1.54) .44  .95 (.49-1.84) .86 
Physical activity .05 (.04.06) 1.08 (0.91-1.29) .31 .05 (.04-.06) 1.11 (0.93-1.32) .21 
Smoking status .05 (.04-.07) 1.24 (0.44-3.47) .68 .07 (.05-.09) 1.14 (0.50-2.61)    .77 
All variables entered independently into hierarchical generalized linear models. 
Age has been grand-centered; all other variables entered uncentered. 
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8.2 DAILY COVARIANCE OF VMS AND NEGATIVE AFFECT 
The first hypothesis was that VMS and negative affect would be associated with each other 
within each 24-hour period. This hypothesis was confirmed.  The association was significant in 
unadjusted and adjusted models with daily VMS set as the outcome, predicted by same day daily 
negative mood (≥2) (table 9), and with daily negative mood (≥2) set as the outcome, predicted by 
same day VMS (table 10).  Older age, poorer health, and perimenopausal status increased the 
likelihood of reporting VMS on a given day, while being Chinese was associated with reduced 
odds of VMS.  The association between education and VMS was no longer significant in the 
fully adjusted model (table 9).  Results for unadjusted and adjusted models were equivalent when 
the continuous daily negative mood variable was used as a predictor (data not shown).  With 
daily negative mood as the outcome, poorer health and perimenopausal status continued to 
increase the likelihood of daily negative mood (≥2), while Black women and older women had 
decreased odds of daily negative mood (table 10).  
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Table 11.  Hypothesis 1:  Association between daily negative mood and daily VMS, adjusted by between-
women covariates 
Outcome:  VMS 
 
 OR (95% CI) p-value 
Unadjusted   
Intercept (VMS) 
 
0.04 (0.03-0.06) <.001 
Slope (negative mood)            1.89 (1.53-2.33) <.001 
Adusted   
Intercept (VMS) 0.02 (0.01-0.05) <.001 
Slope (negative mood) 1.72 (1.39-2.13) <.001 
Age 1.15 (1.04-1.28) .01 
Education   
High school or less 1.60 (.80-3.21) .19 
Some college 1.57 (.84-2.92) .16 
College+ Ref  
Health   
Excellent Ref  
Very Good .76 (.35-1.68) .50 
Good 1.27 (.56-2.90) .57 
Fair/poor 3.70 (1.21-11.35) .02 
Race/ethnicity   
White Ref  
Black .86 (.40-1.83) .69 
Chinese .26 (.13-.54) <.01 
Hispanic .48 (.14-1.68) .25 
Japanese .52 (.25-1.05) .07 
Menopausal status    
Postmenopausal 5.17 (1.01-26.39) .05 
Perimenopausal 3.09 (1.50-6.38) <.01 
Premenopausal Ref  
All daily-level predictors and woman-level covariates simultaneously entered into hierarchical generalized linear 
models. 
Age has been grand-centered; all other variables entered uncentered. 
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Table 12.  Hypothesis 1:  Association between daily VMS and daily negative mood, adjusted by between-
women covariates 
Outcome:  Negative mood (>2) 
 
 OR (95% CI)  p-value 
Unadjusted   
Intercept (negative mood) .06 (.05-.08) <.001 
Slope (VMS) 1.72 (1.39-2.12) <.001 
Adjusted   
Intercept (negative mood) .01 (.00-.01) <.001 
Slope (VMS) 1.76 (1.43-2.17) <.001 
Age 0.87 (0.79-0.96) .01 
Antidepressant use 3.18 (1.49-6.78) <.01 
Health   
Excellent Ref  
Very Good 2.87 (1.48-5.56) <.01 
Good 4.38 (2.17-8.88) <.001 
Fair/poor 13.11 (5.22-32.95) <.001 
Race/ethnicity   
White Ref  
Black .32 (.16-.64) <.01 
Chinese .82 (.41-1.65) .58 
Hispanic 1.88 (.63-5.62) .26 
Japanese .84 (.45-1.58) .59 
Menopausal status    
Postmenopausal .74 (.19-2.85) .66 
Perimenopausal 3.18 (1.65-6.12) <.01 
Premenopausal Ref  
All daily-level predictors and woman-level covariates simultaneously entered into hierarchical generalized linear 
models. 
Age has been grand-centered; all other variables entered uncentered. 
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8.3 NEGATIVE AFFECT AS A PREDICTOR OF NEXT DAY VMS 
The second hypothesis was that negative affect, adjusted by same day VMS, would predict next 
day VMS.  This hypothesis was not confirmed.  Negative mood (≥2) was not associated with 
next day VMS in unadjusted or adjusted models.  In the fully adjusted model, previous day 
VMS, higher age, poor health, and perimenopausal status increased the odds of reporting next 
day VMS; being Chinese was negatively associated with next day VMS (table 11).  Equivalent 
results were found in the unadjusted and adjusted models when using the continuous negative 
mood variable (data not shown).   
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Table 13.  Hypothesis 2:  Association between previous day negative mood and next day VMS, adjusted by 
previous day VMS and between-women covariates 
Outcome:  Next day VMS 
 
 OR (95% CI) p-value 
Unadjusted   
Intercept (VMS) .03 (.03-.04) <.001 
Slope (previous day VMS) 8.62 (7.26-10.24) <.001 
Slope (previous day negative mood) 1.14 (.91-1.43) .26 
Adjusted   
Intercept (VMS) .01 (.01-.03) <.001 
Slope (previous day VMS) 8.96 (7.55-10.64) <.001 
Slope (previous day negative mood) 1.07 (.85-1.35) .55 
Age 1.11 (1.02-1.20) .02 
Education   
High school or less 1.64 (.94-2.84) .08 
Some college 1.48 (.90-2.42) .12 
College+ Ref  
Health   
Excellent Ref  
Very Good .85 (.45-1.59) .60 
Good 1.27 (.65-2.45) .49 
Fair/poor 2.88 (1.20-6.91) .02 
Race/ethnicity   
White Ref  
Black .92 (.50-1.69) .80 
Chinese .34 (.19-.60) <.001 
Hispanic .49 (.18-1.33) .16 
Japanese .57 (.32-.99) .05 
Menopausal status   
Postmenopausal 3.60 (.98-13.19) .05 
Perimenopausal 2.57 (1.42-4.64) <.01 
Premenopausal Ref  
All daily-level predictors and woman-level covariates simultaneously entered into hierarchical generalized linear 
models. 
Age has been grand-centered; all other variables entered uncentered. 
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8.4 VMS AS A PREDICTOR OF NEXT DAY NEGATIVE AFFECT  
The final hypothesis was that VMS, adjusted by same day negative affect, would not predict next 
day negative affect.  This hypothesis was not confirmed.  VMS was significantly associated with 
next day negative affect in unadjusted and adjusted models.  In the fully adjusted model, 
previous day negative mood, antidepressant use, poorer health, and perimenopausal status 
increased the odds of reporting negative mood (≥2) the next day.  Older women and Black 
women were less likely to report next day negative mood (table 12).  
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Table 14.  Hypothesis 3:  Association between previous day VMS and next day negative mood, adjusted by 
previous day negative mood and between-women covariates 
Outcome:  Next day negative mood (>2) 
 
 OR (95% CI) p-value 
Unadjusted   
Intercept (negative mood) .05 (.04-.06) <.001 
Slope (previous day VMS) 1.28 (1.02-1.59) .03 
Slope (previous day negative mood) 4.65 (4.01-5.40) <.001 
Adjusted   
Intercept (negative mood) .00 (.00-.01) <.001 
Slope (previous day VMS) 1.27 (1.03-1.58) .01 
Slope (previous day negative mood) 4.86 (4.20-5.62) <.001 
Age 0.90 (0.83-0.98) .01 
Antidepressant use 2.57 (1.37-4.82) <.01 
Health   
Excellent Ref  
Very Good 2.42 (1.24-4.05) <.01 
Good 3.54 (1.90-6.60) <.001 
Fair/poor 8.74 (4.03-18.96) <.001 
Race/ethnicity   
White Ref  
Black .41 (.23-.73) <.01 
Chinese .82 (.45-1.50) .52 
Hispanic 1.38 (.53-3.53) .51 
Japanese .81 (.48-1.40) .46 
Menopausal status   
Postmenopausal .70 (.22-2.18) .53 
Perimenopausal 2.80 (1.58-4.95) <.01 
Premenopausal Ref  
All daily-level predictors and woman-level covariates simultaneously entered into hierarchical generalized linear 
models. 
Age has been grand-centered; all other variables entered uncentered. 
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8.5 SECONDARY ANALYSES 
The first hypothesis was confirmed with positive mood in the place of negative mood in 
unadjusted and adjusted models; higher positive mood reduced the risk of VMS, and VMS was 
associated with lower positive mood.  For hypotheses 2 and 3, no relationship was seen between 
positive affect and next day VMS, nor between VMS and next day positive affect (data not 
shown). 
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9.0 DISCUSSION 
This study utilized prospective daily diary reports of mood and VMS to expand our current 
understanding of the commonly reported relationship between these factors.  In this sample of 
women in the menopausal transition, higher average negative affect over the course of daily 
diary collection was associated with an increased risk of ever reporting VMS.  On a day-to-day 
basis, higher negative affect was positively associated with VMS within each 24-hour period.  
This relationship was maintained regardless of whether negative affect or VMS was the 
predicted outcome. This study also sought to shed light on the potential directionality of effect 
between these factors.  Contrary to hypotheses, negative affect, adjusted by VMS, was not 
associated with next day VMS.   However, VMS, adjusted by negative affect, was associated 
with next day negative affect.  
The daily association between negative affect and VMS mirrors the common association 
between these factors found in the literature.  However, this association is generally seen with 
retrospective recall of VMS and mood symptoms in previous weeks.  Usual measurement casts 
doubt on this relationship, with the introduction of retrospective recall bias that may be 
influenced by current mood.  Our results suggest that the often-reported association between 
negative affect and VMS on a daily as well as general basis, and exist even with limited bias 
from retrospective reporting.  
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This study also offers a contribution to our understanding of the temporal relationship 
between negative affect and VMS.  It was hypothesized that negative mood would precede VMS, 
due in part to the potential influence of negative mood on the subjective experience of 
symptoms.  Negative mood may increase awareness of and attention to bodily sensations, 
increase symptom sensitivity, and decrease symptom tolerance (Thurston, 2008a).  Women 
experiencing negative mood may be more likely to negatively interpret bodily sensations, and to 
amplify the experience due to attentional bias, leading to increased reporting and possible over-
reporting due to misinterpreted signals (Hunter, 2010).  However, the findings in this study did 
not support this relationship.  Negative affect, adjusted by VMS, was not associated with next 
day VMS.  While this may indicate that negative affect preceding VMS is not the temporal 
relationship that exists between these factors, alternate explanations are also possible.  The 
ability to predict VMS from previous-day mood may have been limited by the small amount of 
within-woman variance in symptom occurrence in this study.  Further, 24-hour periods may not 
have been the appropriate timeframe in which to see this effect. In Thurston et al. (2005), self-
reported VMS were more likely within 30 minutes of increased frustration.  Our ability to detect 
such transient changes in mood and VMS experience was limited, and acute effects of negative 
mood on subjective symptom experience may have been better captured with more frequent data 
collection.  It is also possible that a longer, rather than shorter, timeframe would have yielded 
significant results.  If sustained negative mood is necessary to influence subjective symptom 
experience, accumulated negative mood indicative of periods of increased stress or general 
negative affectivity, rather than a single day’s fluctuation, could predict later VMS.  Future 
research should address these variations in temporal resolution.    
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An alternate theory of temporal association is that VMS leads to increased negative 
mood.  Women often report distress and embarrassment due to symptom experience, particularly 
when they occur in public (Kronenberg, 1990).  Women vary in their behavioral and emotional 
reactions to these unpredictable and uncontrollable events, but those who report them as more 
distressing and bothersome in general may experience negative thoughts during and about the 
symptoms as well as a catastrophization of symptoms.  These negative cognitive appraisals may 
be transient and limited to the duration of symptom experience, or could extend into more 
persistent negative beliefs about the self and the menopausal transition (Hunter, 2010).  
Symptoms may therefore precede subsequent negative mood for a short or longer period of time 
by activating negative schemas and triggering feelings of lack of control, embarrassment, and 
shame.  This theory is particularly related to the experience of daytime VMS, or hot flashes.  
Nighttime VMS, or night sweats, may lead to next-day negative mood by alternate mechanisms.  
The domino hypothesis posits that sleep disturbance resulting from night sweats leads to next-
day impairment and negative mood.  With frequent VMS, this cycle of chronic sleep disruption 
and impaired daytime functioning and well-being may lead to significant depressive symptoms.  
Studies testing this theory result in mixed findings, with a noted disparity between self-reported 
and objectively measured sleep disruptions due to VMS (Joffe, 2009).   Though the mechanism 
linking VMS to subsequent negative mood in this sample is unclear, this temporal relationship 
was supported by our findings, in which VMS, adjusted by negative affect, was associated with 
next day negative affect.  These results suggest that daily changes in negative mood do not 
increase risk of day-to-day VMS, while VMS does have a significant impact on day-to-day 
mood. 
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Additional factors may play a role in these relationships, and should be investigated in 
future studies.  Despite significant associations, little variance in either VMS or mood outcomes 
was explained by the daily predictors and woman-level covariates.  Unmeasured factors related 
to both outcomes may remain to better explain these relationships.  These may include hormonal 
fluctuations (Joffe, 2007), measures of somatization (Thurston, 2005), and self-reported sleep 
disturbance (Kravitz, 2008).  Further, within the explored predictors, specific aspects of mood 
may have differential associations with VMS.  While negative and positive mood were 
correlated, findings related to the temporal relationship between VMS and each mood factor 
differed.  VMS increased the risk of higher negative mood the following day, without an 
associated decrease in positive mood.  This may suggest that VMS contributes to a specific 
aspect of negative mood over time, rather than just increasing negative relative to positive affect 
on a daily basis.  An investigation into individual mood components is warranted in the future.  
Several commonly reported correlates of traditionally measured VMS were also seen 
with the overall and daily reports of VMS in this prospective daily diary collection.  As with past 
investigations, the risk of ever reporting VMS increased with age (Gold, 2006), poorer health 
(Dennerstein, 2003), and perimenopausal status (Gold, 2006).  The risk of reporting VMS on any 
given day was also associated with these factors, as well as with postmenopausal status and 
lower educational attainment.  These associations were consistent with past investigations of 
traditionally-measured VMS (Gold, 2006; Schwingl, 1994), and, with the exception of 
educational attainment, maintained when entered into models simultaneously.  
Some factors commonly associated with VMS did not exhibit a relationship in this 
sample.  Physical activity was not linked to VMS in this sample, contrary to the findings of some 
studies (Gold, 2004) but consistent with others (Greendale, 2005).  This association may be 
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better explained by the relationship between overall physical health and VMS.  Smoking may 
increase risk of VMS, potentially through its effects on estradiol and estrone levels (Gold, 2004), 
but a relationship with current smoking was not seen in our sample.  Few women (9.2%) in our 
sample reported current smoking; results may differ with a higher prevalence of smoking and/or 
with assessment of smoking history.  Black women are thought to have more VMS and Asian 
women less VMS than White women (Gold, 2006).  While overall and daily VMS reporting 
varied significantly by race/ethnicity, this effect was driven by the reduced reporting seen only in 
Chinese women relative to other ethnic groups.  Increased bother related to VMS, independent of 
VMS frequency, has also been seen in Black women compared to White women (Thurston, 
2008).  The high level of bother attributed to VMS experience by Black women may contribute 
to inflated retrospective reporting.  Daily prospective reporting, with decreased retrospective 
bias, may better sample the true symptom experience of this population.  The reporting patterns 
in the other ethnic groups are relatively consistent with past findings in SWAN (Gold, 2006; 
Gold 2000).  Finally, BMI had no association with VMS in this sample, though increased BMI 
has been seen to increase risk of VMS in numerous cross-sectional and longitudinal studies, 
including SWAN (Thurston, 2009b).     
Some additional findings in this study deserve mention.  Past studies utilizing 
retrospectively self-reported VMS have indicated that VMS occur on a daily basis at some point 
in the menopausal transition for 20-25% of women (Freeman, 2005).  In contrast, the findings of 
this study suggest that the majority of women who experience VMS do not have them daily; only 
6.1% of symptomatic women reported VMS on every observation, while 56.7% of symptomatic 
women reported symptoms on just 2-30% of their daily observations (data not shown).  
Prospective daily diary reporting may provide a more accurate representation of symptom 
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frequency, with limited retrospective recall bias and error.  The menopausal transition is also 
considered a vulnerable period for higher levels of depressive symptoms (Bromberger, 2010).  In 
this sample, prospective ratings of negative mood were very low, with most women reporting no 
to little endorsement of negative mood symptoms on a daily basis.  In contrast, positive mood 
ratings were consistently relatively high.  This snapshot of the menopausal transition did not 
appear to represent a period of highly negative mood as measured with prospective daily reports 
in our large, multiethnic, largely perimenopausal sample. 
Several limitations of this study should be noted.  As previously discussed, the 
relationship between mood and daytime hot flashes or night sweats may differ, but the time at 
which VMS occurred cannot be determined in this study.  Frequency, severity, and bother of 
VMS were also not assessed, and these characteristics of VMS experience may play an important 
role in the relationship between daily VMS and daily mood (Thurston, 2008).  Interpretation of 
these findings is also limited by the low levels and limited heterogeneity of daily negative mood 
reported in this sample, as the negative mood reported may not be of meaningful severity.  
Finally, the generalizability of this highly compliant, highly motivated sample is limited.  In 
addition to annual SWAN visits, these women complied with annual completion of a month or 
more of daily diaries and daily urine collection.   
This study also has considerable strengths.  Foremost among these is the contribution of 
prospective daily measurement of mood and VMS, rather than the typical 2 week retrospective 
recall.  This both confirms the stable relationship typically seen between these factors and 
elucidates the relationship between these transient and fluctuating factors on a day-to-day basis, 
adjusting by stable woman-level characteristics related to symptom experience.  The size of the 
sample and length of data collection lends validity, model stability, and the ability to examine 
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over 21,000 separate observations.  The multiethnic makeup of the sample provides valuable 
information about symptom experience in understudied populations.  Finally, the large number 
of symptomatic women in this sample provided novel information about day to day symptom 
experience in a diverse sample of women in the menopausal transition.   
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10.0 CONCLUSIONS 
This study contributes to our knowledge about the relationship between negative affect and 
VMS.  The association between these factors commonly observed in studies using traditional 
retrospective measurement of VMS continued to be seen when mood and VMS were 
prospectively reported in daily diaries.  Researchers should be assured that prospective daily 
measurement of VMS largely replicates findings of studies using typical retrospective 
measurement, though frequency estimates may be inflated.  Assessment of temporal 
relationships between these factors suggests that VMS precedes elevated daily negative affect, 
while daily fluctuations in negative affect do not increase the likelihood of VMS.  Women with 
VMS may be at increased risk for subsequent negative mood symptoms.  Health care 
practitioners should be aware of this potential detrimental effect of VMS experience in 
menopausal women, and consider addressing VMS as an appropriate route to alleviating both 
VMS and mood symptoms in the menopausal transition.  Women and practitioners should be 
aware that negative mood symptoms do not appear to be causing or creating VMS, which may 
alleviate feelings of guilt or responsibility in women who are concerned that their emotional 
states are creating false symptoms.  This study takes us one step closer toward better 
understanding the relationship between negative mood and VMS, which may help influence 
intervention strategies to improve quality of life and health in women as and after they traverse 
the menopause.   
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APPENDIX A 
HIERARCHICAL GENERALIZED LINEAR MODEL EQUATIONS 
 
 
 
Model Building: 
 
Intercepts-only models: 
η= γ00 + u0 + r 
 
Means-as-outcomes models: 
η= γ00 + γ01*Covariate + u0 + r 
 
Random-coefficients models: 
for one level 1 predictor (ie, hypothesis 1): 
η= γ00 + γ 10*Predictor + u0 + u 1*Predictor + r  
 
for two level 2 predictors (ie, hypotheses 2 and 3): 
η= γ00 + γ 10*Predictor1 + γ 20*Predictor2 + u 0 + u 1*Predictor1 + u 2*Predictor2 + r 
 
Slopes-and-intercepts as outcomes models: 
η= γ00 + γ01*Covariate + γ10*Predictor + γ 11*Covariate*Predictor + u 0 + u 1*Predictor + r 
 
For all equations, “covariate” refers to between-women variables, and “predictor” refers to within-woman 
variables 
 
Hypothesis Testing: 
 
Hypothesis 1:  VMS and negative mood will covary within each 24-hour period 
 
Unadjusted, VMS as outcome 
η=γ00 + γ10*negative mood + u0 + u1*negative mood + r 
 
Adjusted, VMS as outcome 
η=γ00 + γ01*age + γ02*education (high school or less) + γ03*education (some college) + γ04*self-rated health (very 
good) + γ05*self-rated health (good) + γ06*self-rated health (poor) + γ07*race/ethnicity (Black) + γ08*race/ethnicity 
(Chinese) + γ09*race/ethnicity (Hispanic) + γ010*race/ethnicity (Japanese) + γ011*Menopausal status 
(postmenopausal) + γ012*Menopausal status (perimenopausal) + γ10*negative mood + u0 + u1*negative mood + r 
 
Unadjusted, negative mood as outcome 
η=γ00 + γ10*VMS + u0 + u1*VMS + r 
 
Adjusted, negative mood as outcome 
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η=γ00 + γ01*age + γ02*antidepressant use + γ03*self-rated health (very good)  + γ04*self-rated health (good) + 
γ05*self-rated health (poor)  + γ06*race/ethnicity (Black)  + γ07*race/ethnicity (Chinese) + γ08*race/ethnicity 
(Hispanic)  + γ09*race/ethnicity (Japanese) + γ010*Menopausal status (postmenopausal)  + γ011*Menopausal status 
(perimenopausal) + γ10*VMS + u0 + u1*VMS + r 
 
Hypothesis 2:  Negative mood will be associated with next day VMS 
 
Unadjusted 
η=γ00 + γ10*lagged VMS + γ20*lagged negative mood + u0 + u1*lagged VMS + u2*lagged negative mood + r 
 
Adjusted 
η=γ00 + γ01*age + γ02*education (high school or less) + γ03*education (some college) + γ04*self-rated health (very 
good) + γ05*self-rated health (good) + γ06*self-rated health (poor) + γ07*race/ethnicity (Black) + γ08*race/ethnicity 
(Chinese) + γ09*race/ethnicity (Hispanic) + γ010*race/ethnicity (Japanese) + γ011*menopausal status 
(postmenopausal) + γ012*menopausal status (perimenopausal) + γ10*lagged VMS + γ20*lagged negative mood + u0 + 
u1*lagged VMS + u2*lagged negative mood + r  
 
Hypothesis 3:  VMS will be associated with next day negative mood 
 
Unadjusted 
η=γ00 + γ10*lagged VMS + γ20*lagged negative mood + u0 + u1*lagged VMS + u2*lagged negative mood + r 
 
Adjusted 
η=γ00 + *age + γ02*antidepressant use + γ03*self-rated health (very good) + γ04*self-rated health (good) + γ05*self-
rated health (poor) + γ06*race/ethnicity (Black) + γ07*race/ethnicity (Chinese) + γ08*race/ethnicity (Hispanic) + γ09*race/ethnicity (Japanese) + γ010*menopausal status (postmenopausal) + γ011*menopausal status (perimenopausal) 
+ γ10*lagged VMS + γ20*lagged negative mood + u0 + u1*lagged VMS + u2*lagged negative mood + r 
 
 
 
Legend: 
  
η:  Outcome 
γ00:  Intercept 
γ0x:  Slope term for level 2 explanatory variable x γ1x:  Slope term for level 1 explanatory variable x 
u0:  Unique increment to the intercept associated with level 2 grouping variable 
ux:  Unique increment to the slope associated with level 2 grouping variable 
r:  Level 1 residual variance 
bold italics:  grand-centered term 
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